WDNA — WisdomTree BioRevolution Fund
Data updated: 2026-08-31
WDNA — WisdomTree BioRevolution Fund. United States Multi-Cap / All-Cap Growth Health Care Equity · $2.68M AUM. Holdings, fees, performance and SEC filings.
WDNA Fund Overview
WDNA — WisdomTree BioRevolution Fund is a US ETF managed by WisdomTree Trust, categorised as United States Multi-Cap / All-Cap Growth Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: WisdomTree Trust
- Category: United States Multi-Cap / All-Cap Growth Health Care Equity
- Assets under management: $2.68M
- 1-year return: 59.8%
- Ticker: WDNA
- SEC CIK: 0001350487
- SEC series ID: S000071961
- Share class ID: C000227588
WDNA Holdings
Top 10 holdings of WisdomTree BioRevolution Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Twist Bioscience Corp. | 5.95% |
| Moderna, Inc. | 4.14% |
| Eli Lilly & Company | 4.08% |
| Johnson & Johnson | 2.97% |
| United Therapeutics Corp. | 2.45% |
| Natera, Inc. | 2.32% |
| Tempus Ai, Inc. | 2.28% |
| Immunome, Inc. | 2.26% |
| Structure Therapeutics, Inc. | 2.11% |
| Stoke Therapeutics, Inc. | 2.09% |
WDNA Portfolio Allocation
Asset-class allocation of WisdomTree BioRevolution Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 0.1% |
WDNA Performance
Total returns for WDNA (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 21.8% |
| 1 year | 59.8% |
| 3 years (annualised) | 7.9% |
| 5 years (annualised) | -3.8% |
WDNA Risk Information
Risk metrics for WDNA, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.7%
WDNA Costs and Fees
WDNA costs about $45 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.45%
- Gross expense ratio: 0.45%
- Portfolio turnover: 32%
- Brokerage commissions: 1.77 bps of average net assets (SEC N-CEN)
WDNA Cashflows
Over the 12 months to 2026-06, WisdomTree BioRevolution Fund had net outflows of $357.99K, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | $0 |
| 2026-05 | $0 |
| 2026-04 | $0 |
| 2026-03 | $0 |
| 2026-02 | −$357.99K |
| 2026-01 | $0 |
WDNA Debt Constituents
No individual debt constituents are reported in WisdomTree BioRevolution Fund's latest SEC N-PORT filing.
WDNA Prospectus and SEC Filings
Official WisdomTree BioRevolution Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-10-28
- Prospectus (485BPOS) — filed 2024-10-28
- Prospectus supplement (497) — filed 2024-03-15
- Portfolio holdings (N-PORT) — filed 2026-08-31
- Portfolio holdings (N-PORT) — filed 2026-06-01
- Portfolio holdings (N-PORT) — filed 2026-02-27
- Annual census (N-CEN) — filed 2025-09-15
- Annual census (N-CEN) — filed 2024-09-12
Related Funds
Other United States Multi-Cap / All-Cap Growth Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.